SPX4:LSE:LSE-SPDR® S&P 400 US Mid Cap UCITS ETF GBP (GBP)

ETF | Others |

Last Closing

USD 69.48

Change

-1.45 (-2.04)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-1.70 (-0.83%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.07 (-0.47%)

USD 640.06B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.02 (+0.09%)

USD 640.06B
0R1I:LSE NVIDIA Corp.

+2.50 (+1.88%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
PRJU:LSE Amundi Index Solutions - Amund..

-0.04 (-0.13%)

USD 269.13B
0QZK:LSE Coca-Cola Co.

-0.25 (-0.35%)

USD 266.08B
0QZO:LSE 0QZO

-0.80 (-0.71%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

+0.60 (+0.39%)

USD 202.26B
0R24:LSE Intel Corp.

+0.18 (+0.84%)

USD 196.14B

ETFs Containing SPX4:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.40% 10% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.40% 10% F 19% F
Trailing 12 Months  
Capital Gain -3.45% 20% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.45% 18% F 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.42% 51% F 59% D-
Dividend Return 7.42% 50% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.05% 66% D+ 81% B-
Risk Adjusted Return 73.86% 74% C 84% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike